Sangamo Therapeutics (formerly known as Sangamo BioSciences) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. It is engaged in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs), which can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off.